Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1U01FD008429-01 | U.S. FDA Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Food and Drug Administration (FDA) | FED |
Not provided
Not provided
Not provided
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives.
Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.
The study may be extended to 3 years to include yearly visits.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 20 HD-ISS Stage 2 | (CAG ≥ 40 and sign/symptom of HD) with or without a support person or family member |
| |
| 20 HD-ISS mild or moderate Stage 3 | (CAG ≥40 and sign symptom and functional impact) with or without a support person or family member |
| |
| 20 Healthy controls | age and sex-matched |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ActiGraph LEAP | Device | The ActiGraph LEAP has received 510(k) clearance from the US FDA and offers extensive sensor collections, providing continuous digital measures of activity, sleep, mobility, and additional vital signs, including heart rate and variability, oxygen saturation, and skin temperature, in a single fit-for-purpose device. |
| Measure | Description | Time Frame |
|---|---|---|
| Inter-Method Reliability of Total Time in Chorea (Trunk-Worn vs. Wrist-Worn Device) | Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants. | 1 week |
| Known Group Validity of Total Time in Chorea (Trunk-Worn Device) | Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants. | 1 week |
| Known Group Validity of Total Time in Chorea (Wrist-Worn Device) | Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants. | 2 weeks |
| Inter-Method Reliability of Stride Time Variability (Trunk-Worn vs. Wrist-Worn Device) | Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the agreement between trunk-worn and wrist-worn devices among HD and control participants. | 1 week |
| Known Group Validity of Stride Time Variability (Trunk-Worn Device) | Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the ability of the trunk-worn device to differentiate between HD and control participants. |
Not provided
Not provided
Inclusion Criteria:
Inclusion Criteria for participants with adult-onset HD:
Inclusion Criteria for control participants:
Inclusion Criteria for support persons:
Exclusion Criteria:
Not provided
Not provided
This study will enroll 60 participants: 20 HD-ISS Stage 2 (CAG ≥ 40 and sign/symptom of HD) with or without a support person or family member; 20 HD-ISS mild or moderate Stage 3 (CAG ≥ 40 and sign symptom and functional impact) with or without a support person or family member; and 20 controls (age and sex-matched). Participants will not be excluded based on ethnicity, and no subpopulations will be excluded from this study. We will exert specific efforts to ensure the inclusion of minorities, including the Black and Hispanic populations
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sugitha Maheswaran, BS | Contact | 5857040344 | Sugi_maheswaran@urmc.rochester.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Rochester Medical Center | Recruiting | Rochester | New York | 14642 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006816 | Huntington Disease |
| ID | Term |
|---|---|
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Axivity AX6 | Device | The Axivity AX6 is a data logger capable of recording raw data from a suite of integrated sensors. It features a state of the art 6-Axis movement sensor measuring linear acceleration and angular velocity at high precision. All sensor locations and Orientations are identical to the AX3 for maximum compatibility. All data is stored in its raw, unaltered format on the embedded flash memory. |
|
| 1 week |
| Known Group Validity of Stride Time Variability (Wrist-Worn Device) | Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants. | 2 weeks |
| D003704 | Dementia |
| D002819 | Chorea |
| D020820 | Dyskinesias |
| D009069 | Movement Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |